Wei Yan Ng1, Gavin Siew Wei Tan2, Peng-Guan Ong3, Ching-Yu Cheng4, Carol Yim-Lui Cheung4, Doric Wen Kuan Wong5, Ranjana Mathur5, Khuan Yew Chow6, Tien Yin Wong2, Gemmy Chui Ming Cheung7. 1. Singapore National Eye Centre, Singapore. 2. Singapore National Eye Centre, Singapore; Singapore Eye Research Institute, Singapore; Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Ophthalmology Academic Clinical Program, Duke-National University of Singapore Graduate Medical School, Singapore. 3. Singapore Eye Research Institute, Singapore. 4. Singapore Eye Research Institute, Singapore; Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Ophthalmology Academic Clinical Program, Duke-National University of Singapore Graduate Medical School, Singapore. 5. Singapore National Eye Centre, Singapore; Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Ophthalmology Academic Clinical Program, Duke-National University of Singapore Graduate Medical School, Singapore. 6. National Registry of Diseases Office, Singapore. 7. Singapore National Eye Centre, Singapore; Singapore Eye Research Institute, Singapore; Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Ophthalmology Academic Clinical Program, Duke-National University of Singapore Graduate Medical School, Singapore. Electronic address: gemmy.cheung.c.m@snec.com.sg.
Abstract
PURPOSE: To describe the rates of myocardial infarction (MI), stroke, and mortality in patients who have treatment with intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections for age-related macular degeneration (AMD). DESIGN: A retrospective population linkage study. METHOD: We identified patients aged 40 years and above who received treatment with intravitreal anti-VEGF injections for AMD from January 1, 2008 to December 31, 2011 at the Singapore National Eye Centre. We used a national record linkage database to identify patients who developed MI, stroke, and all-cause mortality after the first injection, excluding those with previous MI or stroke at baseline from the respective analysis. We compared rates of MI, stroke, and mortality to that of the total Singapore population. RESULTS: A total of 1182 individuals had an intravitreal anti-VEGF injection included in this analysis, with the majority receiving bevacizumab (n = 1011). Overall, 19 patients developed MI, 16 developed stroke, and there were 43 mortalities, giving an age-adjusted incidence rate of 350.2 per 100 000 person-years for MI, 299.3 per 100 000 person-years for stroke, and 778.9 per 100 000 person-years for mortality. This is comparable to the weighted incidence rates of the Singapore population (427.1 per 100 000 person-years for MI, 340.4 per 100 000 person-years for stroke, and 921.3 per 100 000 person-years for mortality). CONCLUSION: The incidence rate of MI, stroke, and death in this cohort of AMD patients treated with anti-VEGF was low, and was not significantly higher than the age-adjusted incidence rate of these events in the Singapore population.
PURPOSE: To describe the rates of myocardial infarction (MI), stroke, and mortality in patients who have treatment with intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections for age-related macular degeneration (AMD). DESIGN: A retrospective population linkage study. METHOD: We identified patients aged 40 years and above who received treatment with intravitreal anti-VEGF injections for AMD from January 1, 2008 to December 31, 2011 at the Singapore National Eye Centre. We used a national record linkage database to identify patients who developed MI, stroke, and all-cause mortality after the first injection, excluding those with previous MI or stroke at baseline from the respective analysis. We compared rates of MI, stroke, and mortality to that of the total Singapore population. RESULTS: A total of 1182 individuals had an intravitreal anti-VEGF injection included in this analysis, with the majority receiving bevacizumab (n = 1011). Overall, 19 patients developed MI, 16 developed stroke, and there were 43 mortalities, giving an age-adjusted incidence rate of 350.2 per 100 000 person-years for MI, 299.3 per 100 000 person-years for stroke, and 778.9 per 100 000 person-years for mortality. This is comparable to the weighted incidence rates of the Singapore population (427.1 per 100 000 person-years for MI, 340.4 per 100 000 person-years for stroke, and 921.3 per 100 000 person-years for mortality). CONCLUSION: The incidence rate of MI, stroke, and death in this cohort of AMDpatients treated with anti-VEGF was low, and was not significantly higher than the age-adjusted incidence rate of these events in the Singapore population.
Authors: Lauren A Dalvin; Matthew R Starr; Jackson E AbouChehade; Gena M Damento; Maria Garcia; Saumya M Shah; David O Hodge; Irene Meissner; Sophie J Bakri; Raymond Iezzi Journal: JAMA Ophthalmol Date: 2019-05-01 Impact factor: 7.389
Authors: M Rinaldi; F Semeraro; F Chiosi; A Russo; M R Romano; M C Savastano; R dell'Omo; C Costagliola Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-09-28 Impact factor: 3.117
Authors: Daniel A Benisek; Julio Manzitti; Daniel Scorsetti; Andres M Rousselot Ascarza; Amalia A Ascarza; Diego Gomez Rancaño; Romina Quercia; Matias Ramirez Gismondi; Mateo A Carpio Total; María L Scorsetti; Eduardo Spitzer; Carola Lombas; Matías Deprati; María Ines Penna; Francisco Fernández; Marcelo A Tinelli Journal: Exp Ther Med Date: 2020-10-09 Impact factor: 2.447